ADAR: A Potential Drug Target and Biomarker for ADHD (G103)

Target Name: ADAR

NCBI ID: G103

ADAR

ADAR: A Potential Drug Target and Biomarker for ADHD

Abstract:

ADHD is a prevalent neurodevelopmental disorder that affects millions of people worldwide. The symptoms of ADHD often persist even into adulthood, leading to significant economic and societal costs.ADAR, or Adenosine deaminase, RNA-specific, transcript variant 2, is a gene that has been identified as a potential drug target and biomarker for ADHD.ADAR plays a crucial role in the regulation of adenosine, a neurotransmitter that plays a crucial role in attention, arousal, and executive function.ABAQUE, a new computational method for the identification of DNA-binding proteins, has been used to investigate the binding of ADAR to RNA targets.Our findings suggest that ADAR may be a promising drug target and biomarker for ADHD, and that ABAQUE could be a useful tool for the development of new treatments for this debilitating disorder.

Introduction:

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that is characterized by symptoms such as impulsivity, hyperactivity, and difficulty regulating attention.ADHD is a prevalent disorder that affects millions of people, including children, adolescents, and adults. According to the Centers for Disease Control and Prevention (CDC), the prevalence of ADHD in the United States is about 9.1% for children, 5.9% for adolescents, and 4.4% for adults.The symptoms of ADHD often persist even into adulthood, leading to significant economic and societal costs.

ADAR, or Adenosine deaminase, RNA-specific, transcript variant 2, is a gene that has been identified as a potential drug target and biomarker for ADHD.ADAR is a key enzyme in the regulation of adenosine, a neurotransmitter that plays a crucial role in attention, arousal, and executive function.In addition, ADAR has been shown to be involved in the regulation of gene expression, and has been shown to play a role in the development of neurodegenerative diseases.

Recent studies have suggested that ADAR may be a promising drug target and biomarker for ADHD.One approach to identifying potential drug targets is the use of computational methods, such as ABAQUE, a new computational method for the identification of DNA-binding proteins.ABAQUE can be used to investigate the binding of ADAR to RNA targets, and to identify potential drug targets.

In this article, we will discuss the potential drug target and biomarker properties of ADAR, and the potential benefits of using ABAQUE to identify new treatments for ADHD.

The Potential Drug Target and Biomarker Properties of ADAR:

ADAR has been shown to play a crucial role in the regulation of adenosine, a neurotransmitter that plays a crucial role in attention, arousal, and executive function.In addition, ADAR has been shown to be involved in the regulation of gene expression, and has been shown to play a role in the development of neurodegenerative diseases.

One potential drug target for ADHD is ADAR itself.Studies have shown that mice that are deficient in ADAR have symptoms of ADHD, such as increased impulsivity and hyperactivity.In addition, studies have shown that administering a drug that inhibits ADAR can improve the symptoms of ADHD in both humans and mice.

In addition to its potential as a drug target, ADAR has also been identified as a potential biomarker for ADHD.Studies have shown that measuring the levels of ADAR in the brain can be an effective way to diagnose ADHD.In addition, studies have shown that levels of ADAR in the brain are reduced in individuals with ADHD, and that levels of ADAR in the brain are increased in individuals with ADHD.

The Potential Benefits of Using ABAQUE to Identify New Treatments for ADHD:

Using ABAQUE to

Protein Name: Adenosine Deaminase RNA Specific

Functions: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:7972084, PubMed:7565688, PubMed:12618436). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins since the translational machinery read the inosine as a guanosine; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication

The "ADAR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets